Table 1.
Clinical data of patients progressed
| Local recurrence | Non- local recurrence | p value | |
|---|---|---|---|
| Mean age | 59 | 58 | 0.312 |
| T1-Gd preoperative volume | 36.7 cc | 49.9 cc | <0.001* |
| T2-FLAIR preoperative volume | 92.73 cc | 81.75 cc | 0.933 |
| Karnofsky | |||
| 70–100 | 72 % | 28 % | 0.175 |
| <70 | 54 % | 46 % | |
| MGMT | |||
| Methylated | 59 % | 41 % | 0.107 |
| Non-methylated | 68 % | 32 % | |
| Extend of resection | |||
| CRET | 59 % | 41 % | 0.412 |
| No CRET | 79 % | 21 % | |
| Included in vaccine trial | 46 % | 52 % | 0.307 |
| Median PFS | 6.4 | 13.8 | 0.019* |
| Median OS | 19.3 | 24 | 0.9 |
CRET complete resection of enhanced tumor, PFS progression free survival, OS overall survival